{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T01:29:23Z","timestamp":1787016563727,"version":"build-2736575974"},"reference-count":0,"publisher":"American Association for the Advancement of Science (AAAS)","issue":"6662","content-domain":{"domain":["www.science.org"],"crossmark-restriction":true},"short-container-title":["Science"],"published-print":{"date-parts":[[2023,9,8]]},"abstract":"<jats:p>There are no cures for the most common neurodegenerative diseases. None of the currently approved treatments cure or halt these conditions; rather, they address symptoms or slow disease progression. A focus on protein deposits in the brain\u2014a hallmark of Alzheimer\u2019s disease (AD) and Parkinson\u2019s disease (PD)\u2014has led to the development of immunotherapy drugs. Other promising avenues of investigation include the roles of neuroinflammation in neurodegeneration. However, the clinical impact of these approaches is still uncertain. What about exploiting our knowledge of the human genome and the ability to modify it with surgically precise tools? Can functional genomics approaches in neurodegenerative disease research provide the breakthroughs we need?<\/jats:p>","DOI":"10.1126\/science.adk5693","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T13:58:56Z","timestamp":1694095136000},"update-policy":"https:\/\/doi.org\/10.34133\/aaas_crossmark","source":"Crossref","is-referenced-by-count":12,"title":["Neurodegeneration enters the era of functional genomics"],"prefix":"10.1126","volume":"381","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0344-6708","authenticated-orcid":true,"given":"Adriano","family":"Aguzzi","sequence":"first","affiliation":[{"name":"Adriano Aguzzi is at the Institute of Neuropathology, University of Zurich, CH-8091 Zurich, Switzerland."},{"name":"Martin Kampmann is in the Department of Biochemistry and Biophysics and Institute for Neurodegenerative Diseases, University of California, San Francisco, CA 94158, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3819-7019","authenticated-orcid":true,"given":"Martin","family":"Kampmann","sequence":"additional","affiliation":[{"name":"Adriano Aguzzi is at the Institute of Neuropathology, University of Zurich, CH-8091 Zurich, Switzerland."},{"name":"Martin Kampmann is in the Department of Biochemistry and Biophysics and Institute for Neurodegenerative Diseases, University of California, San Francisco, CA 94158, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"221","container-title":["Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.science.org\/doi\/full\/10.1126\/science.adk5693","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,15]],"date-time":"2024-01-15T19:03:35Z","timestamp":1705345415000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.science.org\/doi\/10.1126\/science.adk5693"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,8]]},"references-count":0,"journal-issue":{"issue":"6662","published-print":{"date-parts":[[2023,9,8]]}},"alternative-id":["10.1126\/science.adk5693"],"URL":"https:\/\/doi.org\/10.1126\/science.adk5693","relation":{},"ISSN":["0036-8075","1095-9203"],"issn-type":[{"value":"0036-8075","type":"print"},{"value":"1095-9203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,8]]},"assertion":[{"value":"2023-09-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"eadk5693"}}